

## Evonik set to expand its ThreAMINO® capacity in Europe

May 14, 2012

Evonik Industries (Germany) announces a capacity increase of ThreAMINO® (L-threonine) at Evonik Agroferm Zrt., a 100% affiliated company of Evonik, in Kaba, Hungary. The nameplate capacity is expected to be expanded to 30,000 metric tons L-threonine (feed grade 98.5%) per annum, which represents an increase of 10,000 metric tons. The new capacity is scheduled to come on stream in the third quarter of 2013. The additional quantities shall serve the growing demand.

**Contact person specialized/local press**

**Dr. Jürgen Krauter**  
Communication Health & Nutrition  
Phone +49 61 81 59-6847  
Fax +49 61 81 59-76847  
juergen.krauter@evonik.com

“This expansion will transform the Hungarian site into a world-scale plant with state-of-the-art technology. It is our ambition that all investment projects lead to a significant performance improvement of the process and the product form. This shall help us to meet rising needs and requirements of our customers,” explains Dr Walter Pfefferle, head of Bioproducts business line of Evonik.

The ThreAMINO® expansion complements two recent expansion announcements by Evonik, namely the construction of a new 150,000 metric ton MetAMINO® (DL-methionine) production complex on Jurong Island, Singapore, which is scheduled to come on stream in 2014, and the expansion of Biolys® (L-lysine source) to an annual capacity of 280,000 metric tons in Blair, Nebraska, USA, by the end of 2012.

“The unique Evonik package of essential amino acids and advanced technical and commercial services is intended to create value for our customers,” underlines Dr Alfred Petri, responsible for sales and marketing of Evonik feed amino acids.

L-Threonine, which Evonik is marketing under the brand name ThreAMINO®, is an essential amino acid that cannot be synthesized by the body and therefore needs to be ingested by the animal with the feed. An optimal L-threonine content enhances feed intake, weight gain and the nutritional value of the feed, while nitrogen excretion is reduced by balancing the dietary crude protein content to the animal's requirement.

**Evonik Industries AG**  
Rellinghauser Strasse 1-11  
45128 Essen  
Germany  
www.evonik.com

**Chairman of the Supervisory Board**  
Wilhelm Bonse-Geuking  
**Executive Board**  
Dr. Klaus Engel, Chairman  
Dr. Wolfgang Colberg,  
Dr. Thomas Haeberle, Thomas Wessel,  
Patrik Wohlhauser, Dr. Dahai Yu

Registered Office: Essen  
Register Court: Essen Local Court  
Commercial Registry B 19474  
VAT ID no. DE 811160003

Evonik is the only company in the world that produces and markets all four essential amino acids used in advanced animal nutrition: MetAMINO® (DL-methionine), Biolys® (L-lysine source), ThreAMINO® (L-threonine) and TrypAMINO® (L-tryptophan). The company markets products and services in more than one hundred countries and thus makes a valuable contribution to the cost-efficiency of its customers and to healthy and environment-friendly animal nutrition.

#### **Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (EBITDA) of about €2.8 billion.

#### **Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.